Bluejay Diagnostics, Inc.
BJDXBluejay Diagnostics, Inc.
NASDAQ
Healthcare
Medical - Devices
$1.95
+0.06(3.17%)
52W $1.77 – $30.00
AI-generated
Bluejay Diagnostics, Inc.
$884.4KMkt Cap
—Rev TTM
-$7MNI TTM
-0.1xP/E TTM
Latest Earnings
10-K
FY FY2025Mar 5, 2026Bluejay Diagnostics, Inc. reported a net loss of $6.8 million for fiscal year 2025, an improvement from a net loss of $7.7 million in 2024. The company generated no revenue, with total operating expenses of $7.0 million, primarily driven by research and development ($3.0 million) and general and administrative costs ($3.9 million). Cash and cash equivalents stood at $5.2 million...
What Changed Recently
Fundamentals
How The Business Makes Money
Bluejay Diagnostics, Inc. operates as a medical diagnostics company. The company offers the Symphony platform, a technology platform comprising the Symphony analyzer that orchestrates whole blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and the Symphony Cartridge, which includes reagents and components. It also provides the ALLEREYE diagnostic test, a point-of-care device for the diagnosis of allergic conjunctivitis. In addition, the company develops Symphony IL-6 tests for the monitoring of disease progression in critical care settings. Further, it is developing additional tests for Symphony, such as tests for myocardial infraction and congestive heart failure. Bluejay Diagnostics, Inc. was incorporated in 2015 and is headquartered in Acton, Massachusetts.
Industry Medical - Devices
Analyst View
Company Profile
CIK0001704287
ISINUS0956336087
CUSIP095633608
Phone844 327 7078
Address360 Massachusetts Avenue, Acton, MA, 01720, US
SEC EDGAR